Dianthus Therapeutics Inc. (NASDAQ:DNTH) — Market Cap & Net Worth
Market Cap & Net Worth: Dianthus Therapeutics Inc. (DNTH)
Dianthus Therapeutics Inc. (NASDAQ:DNTH) has a market capitalization of $5.86 Billion ($5.86 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3214 globally and #1137 in its home market, demonstrating a -3.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dianthus Therapeutics Inc.'s stock price $104.77 by its total outstanding shares 55934378 (55.93 Million). Also see DNTH total assets for a full breakdown of the balance sheet.
Dianthus Therapeutics Inc. Market Cap History: 2018 to 2026
Dianthus Therapeutics Inc.'s market capitalization history from 2018 to 2026. Data shows growth from $318.83 Million to $5.86 Billion (27.10% CAGR). Also see DNTH cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Dianthus Therapeutics Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.22% | #80 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.01% | #364 of 3165 |
Weight: Dianthus Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dianthus Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dianthus Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check DNTH share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1132.15x
Dianthus Therapeutics Inc.'s market cap is 1132.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $247.79 Million | $1.48 Million | -$13.11 Million | 167.88x | N/A |
| 2022 | $22.37 Million | $6.42 Million | -$28.48 Million | 3.49x | N/A |
| 2023 | $581.72 Million | $2.83 Million | -$43.55 Million | 205.84x | N/A |
| 2024 | $1.22 Billion | $6.24 Million | -$84.97 Million | 195.57x | N/A |
| 2025 | $2.31 Billion | $2.04 Million | -$162.34 Million | 1132.15x | N/A |
Competitor Companies of DNTH by Market Capitalization
Companies near Dianthus Therapeutics Inc. in the global market cap rankings as of September 16, 2026. Review Dianthus Therapeutics Inc. tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Dianthus Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Dianthus Therapeutics Inc. Historical Marketcap From 2018 to 2026
Between 2018 and today, Dianthus Therapeutics Inc.'s market cap moved from $318.83 Million to $ 5.86 Billion, with a yearly change of 27.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.86 Billion | +154.23% |
| 2025 | $2.31 Billion | +89.04% |
| 2024 | $1.22 Billion | +109.62% |
| 2023 | $581.72 Million | +2500.00% |
| 2022 | $22.37 Million | -90.97% |
| 2021 | $247.79 Million | -43.49% |
| 2020 | $438.53 Million | -48.28% |
| 2019 | $847.97 Million | +165.96% |
| 2018 | $318.83 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Dianthus Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.86 Billion USD |
| MoneyControl | $5.86 Billion USD |
| MarketWatch | $5.86 Billion USD |
| marketcap.company | $5.86 Billion USD |
| Reuters | $5.86 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dianthus Therapeutics Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that target… Read more